Thermo Fisher's $15bn war chest set to further consolidate industry
Danaher's acquisition of Pall will not change the competitive landscape in the bioprocessing tech industry says Thermo Fisher, as it earmarks $10bn for further M&A activity.
Archives for May 21, 2015
US scientists vow to answer CRISPR’s sticky moral questions
Top science academics have launched an initiative to consider emerging human gene-editing tools such as CRISPR-Cas9.
WuXi adding ADC tech to services in Ambrx acquisition
A consortium including WuXi PharmaTech has agreed to acquire biotech client Ambrx for its antibody-drug conjugate (ADC) conjugation technology.
Mammoth undertaking: CRISPR/Cas9 gene editing goes beyond medicine
Big Pharma is not the only slow moving behemoth involved in the CRISPR/Cas9 revolution with a US team citing the gene editing tech as key to its efforts to resurrect the woolly mammoth.